2023-08-28 10:04:12 ET
More on Akebia
- Akebia Therapeutics, Inc. ( AKBA ) Q2 2023 Earnings Call Transcript
- Akebia: 'Hold' Through Regulatory And Financial Hurdles
- Akebia Therapeutics: Take Profits Before Second Quarter Report
- Akebia GAAP EPS of -$0.06 misses by $0.03, revenue of $56.38M misses by $2.72M
- Akebia plans to resubmit vadadustat NDA by end of Q3
- Akebia to resubmit FDA application for kidney drug by end of Q3
- Seeking Alpha’s Quant Rating on Akebia
For further details see:
Akebia spikes as H.C. Wainwright upgrades on potential vadadustat approval